Wednesday, July 8, 2026

Drug profile · INN

bimatoprost

bimatoprost (BIMATOPROST SANDOZ) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Sensory organs (S01) S01EE03
US status approved
Patents linked 9
Pipeline programs 6
News articles 1
Drug details — bimatoprost

Quick answer

bimatoprost (BIMATOPROST SANDOZ) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN bimatoprost
Brand BIMATOPROST SANDOZ
Mechanism Prostanoid FP receptor agonist
Target Prostaglandin F2-alpha receptor
Therapeutic class Sensory organs (S01)
Route OPHTHALMIC
Formulation SOLUTION
ATC code S01EE03

Mechanism of action

Prostanoid FP receptor agonist

Primary target: Prostaglandin F2-alpha receptor

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved

Recent coverage

Pipeline programs

  1. 192024-092 Phase 3 · AbbVie Deutschland GmbH · Ocular hypertension, Open-angle glaucoma
  2. Bimatoprost SR Phase 3 · AbbVie Deutschland GmbH · Open-angle Glaucoma, Ocular Hypertension
  3. Test - Bimatoprost 0.01% Ophthalmic Solution Phase 3 · Amneal Pharma Europe · Glaucoma, Open-Angle
  4. bimatoprost ophthalmic solution formulation A Phase 3 · Allergan Pharmaceuticals International · Glaucoma
  5. Bimatoprost Ophthalmic Solution, 0.01% Phase 1 · Amneal Pharma Europe · Open-angle Glaucoma
  6. Bimatoprost Approved · Cardiff Oncology · Graves' Ophthalmopathy

Related & competitor drugs

  1. aflibercept Sensory organs (S01)
  2. atropine sulfate Sensory organs (S01)
  3. carboprost tromethamine Prostanoid FP receptor agonist
  4. atropine Sensory organs (S01)
  5. brinzolamide Sensory organs (S01)
  6. dinoprost tromethamine Prostanoid FP receptor agonist
  1. CA 3244873

    TRAITEMENT PRÉVENTIF DE LA MIGRAINE

    Expires Wed Sep 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. WO 2023077094

    TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR

    Expires Wed Apr 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 2023130736

    METHODS OF TREATING MIGRAINE

    Expires Wed Apr 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 2022380379

    PHARMACEUTICAL COMPOUNDS

    Expires Wed Nov 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 2021387969

    BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS

    Expires Wed Dec 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. CA 3177686

    COMPOSITIONS COMPRENANT DE LA TROPOELASTINE RETICULEE A DE L'ACIDE HYALURONIQUE ET LEURS PROCEDES D'UTILISATION

    Expires Wed Nov 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. CA 3152006

    TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE

    Expires Wed Feb 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. WO 2020012244

    TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB

    Expires Wed Jan 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. WO 2019016609

    TRAITEMENT DE LÉSIONS NON INFLAMMATOIRES

    Expires Wed Jan 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is bimatoprost?

bimatoprost (BIMATOPROST SANDOZ) is a prostanoid fp receptor agonist. Associated with Alphapharm Pty Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for bimatoprost?

BIMATOPROST SANDOZ is a marketed brand name for bimatoprost. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of bimatoprost?

bimatoprost has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.